Customize your JAMA Network experience by selecting one or more topics from the list below.
Vorgerd M, Grehl T, Jäger M, et al. Creatine Therapy in Myophosphorylase Deficiency (McArdle Disease): A Placebo-Controlled Crossover Trial. Arch Neurol. 2000;57(7):956–963. doi:https://doi.org/10.1001/archneur.57.7.956
To determine whether treatment with creatine can improve exercise intolerance in myophosphorylase deficiency (McArdle disease).
Double-blind, placebo-controlled crossover study with oral creatine monohydrate supplementation.
Nine patients with biochemically and genetically proven McArdle disease were treated.
Five days of daily high-dose creatine intake (150 mg/kg body weight) were followed by daily low-dose creatine intake (60 mg/kg). Each treatment phase with creatine or placebo lasted 5 weeks.
Main Outcome Measures
The effect of treatment was estimated at the end of each treatment phase by recording clinical scores, ergometer exercise test results, phosphorus 31 nuclear magnetic resonance spectroscopy, and surface electromyography.
Of 9 patients, 5 reported improvement of muscle complaints with creatine. Force-time integrals (P = .03) and depletion of phosphocreatine (P = .04) increased significantly during ischemic exercise with creatine. Phosphocreatine depletion also increased significantly during aerobic exercise (P = .006). The decrease of median frequency in surface electromyograms during contraction was significantly larger (P = .03) with creatine.
This is the first controlled study indicating that creatine supplementation improves skeletal muscle function in McArdle disease.
Create a personal account or sign in to: